KIRURGILISED IMPLANTAADID. AKTIIVSED IMPLANTEERITAVAD MEDITSIINISEADMED. OSA 2: SÜDAMESTIMULAATORID

Implants for surgery - Active implantable medical devices - Part 2: Cardiac pacemakers (ISO 14708-2:2019)



# EESTI STANDARDI EESSÕNA

## NATIONAL FOREWORD

See Eesti standard EVS-EN ISO 14708-2:2022 sisaldab Euroopa standardi EN ISO 14708-2:2022 ingliskeelset teksti.

This Estonian standard EVS-EN ISO 14708-2:2022 consists of the English text of the European standard EN ISO 14708-2:2022.

Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas.

This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation and Accreditation.

Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 27.07.2022.

Date of Availability of the European standard is 27.07.2022.

Standard on kättesaadav Eesti Standardimis-ja Akrediteerimiskeskusest.

The standard is available from the Estonian Centre for Standardisation and Accreditation.

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile <u>standardiosakond@evs.ee</u>.

# ICS 11.040.40

Standardite reprodutseerimise ja levitamise õigus kuulub Eesti Standardimis- ja Akrediteerimiskeskusele

Andmete paljundamine, taastekitamine, kopeerimine, salvestamine elektroonsesse süsteemi või edastamine ükskõik millises vormis või millisel teel ilma Eesti Standardimis-ja Akrediteerimiskeskuse kirjaliku loata on keelatud.

Kui Teil on küsimusi standardite autorikaitse kohta, võtke palun ühendust Eesti Standardimis-ja Akrediteerimiskeskusega: Koduleht <a href="https://www.evs.ee">www.evs.ee</a>; telefon 605 5050; e-post <a href="mailto:info@evs.ee">info@evs.ee</a>

The right to reproduce and distribute standards belongs to the Estonian Centre for Standardisation and Accreditation No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, without a written permission from the Estonian Centre for Standardisation and Accreditation.

If you have any questions about copyright, please contact Estonian Centre for Standardisation and Accreditation:

Homepage www.evs.ee; phone +372 605 5050; e-mail info@evs.ee

# **EUROPEAN STANDARD**

# EN ISO 14708-2

# NORME EUROPÉENNE

# **EUROPÄISCHE NORM**

July 2022

ICS 11.040.40

#### **English version**

# Implants for surgery - Active implantable medical devices -Part 2: Cardiac pacemakers (ISO 14708-2:2019)

Implants chirurgicaux - Dispositifs médicaux implantables actifs - Partie 2: Stimulateurs cardiaques (ISO 14708-2:2019)

Chirurgische Implantate - Aktive implantierbare medizinische Geräte - Teil 2: Herzschrittmacher (ISO 14708-2:2019)

This European Standard was approved by CEN on 6 July 2022.

CEN and CENELEC members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN and CENELEC member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN and CENELEC member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN and CENELEC members are the national standards bodies and national electrotechnical committees of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.





**CEN-CENELEC Management Centre:** Rue de la Science 23, B-1040 Brussels

# **European foreword**

This document (EN ISO 14708-2:2022) has been prepared by Technical Committee ISO/TC 150 "Implants for surgery" in collaboration with Technical Committee CEN-CENELEC/ JTC 16 "Active Implantable Medical Devices" the secretariat of which is held by DKE.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by January 2023, and conflicting national standards shall be withdrawn at the latest by January 2023.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN-CENELEC shall not be held responsible for identifying any or all such patent rights.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN and CENELEC websites.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

## **Endorsement notice**

The text of ISO 14708-2:2019 has been approved by CEN-CENELEC as EN ISO 14708-2:2022 without any modification.

Foreword	Coı	ntents	5	Page			
1 Scope 1 2 Normative references 1 3 Terms and definitions 2 4 Symbols and abbreviated terms 5 5 General requirements for non-implantable parts 6 5.1 General requirements for non-implantable parts 6 5.2 General requirements for software 6 5.3 Usability of non-implantable parts 6 5.4 Data security and protection from harm caused by unauthorized information tampering 6 5.5 General requirements for risk management 6 5.6 Misconnection of parts of the active implantable medical device 6 6 Measurements of implantable pulse generator and lead characteristics 6 6.1 Measurement of implantable pulse generator characteristics 6 6.1.1 General considerations 6 6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate 6 6.1.3 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.4 Measurement of inpul impedance (Z <sub>[n]</sub> ) 8 6.1.5 Measurement of is essensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.4 Measurement of is essing refractory period (t <sub>pr</sub> ) 8 6.1.5 Measurement of sensing refractory period (t <sub>pr</sub> ) 10 6.1.6 Measurement of sensing refractory period (t <sub>pr</sub> ) 10 6.1.7 Measurement of pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators) 13 6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators) 13 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 15 6.1 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 15 6.2 Measurement of the atrial-ventricular (AV) interval after sensing 14 6.2.1 Measurement of the atrial-ventricular (AV) interval after sensing 15 6.2 Measurement of the bada pacing impedance (Z <sub>p</sub> ) 16 6.2.1 Measurement of the atrial-ventricular (AV) interval after sensing 15 6.2 Measurement of the bada pacing impedance 16 6.2.1 Measurement of the atrial-ventricular implementable medical device 16 6.2.2 Meth	Fore	word			v		
2         Normative references         1           3         Terms and definitions         2           4         Symbols and abbreviated terms         5           5         General requirements for non-implantable parts         6           5.1         General requirements for non-implantable parts         6           5.2         General requirements for risk management         6           5.4         Data security and protection from harm caused by unauthorized information tampering 6         5.5           5.5         General requirements for risk management         6           5.6         Misconnection of parts of the active implantable medical device         6           6         Measurements of implantable pulse generator and lead characteristics         6           6.1         Measurement of implantable pulse generator characteristics         6           6.1         Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate         6           6.1.1         General considerations         6           6.1.2         Measurement of sensitivity (e pos and e neg)         7           6.1.3         Measurement of sensing refractory period (t <sub>pp</sub> )         8           6.1.5         Measurement of pulse amplitude, pulse generators         10           6.1.7         Measuremen	Intro	oduction	1		vi		
2         Normative references         1           3         Terms and definitions         2           4         Symbols and abbreviated terms         5           5         General requirements for non-implantable parts         6           5.1         General requirements for non-implantable parts         6           5.2         General requirements for risk management         6           5.4         Data security and protection from harm caused by unauthorized information tampering 6         5.5           5.5         General requirements for risk management         6           5.6         Misconnection of parts of the active implantable medical device         6           6         Measurements of implantable pulse generator and lead characteristics         6           6.1         Measurement of implantable pulse generator characteristics         6           6.1         Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate         6           6.1.1         General considerations         6           6.1.2         Measurement of sensitivity (e pos and e neg)         7           6.1.3         Measurement of sensing refractory period (t <sub>pp</sub> )         8           6.1.5         Measurement of pulse amplitude, pulse generators         10           6.1.7         Measuremen	1	Scope	3		1		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2	. ()					
5 General requirements for non-implantable parts 5.1 General requirements for non-implantable parts 5.2 General requirements for non-implantable parts 6.5.1 General requirements for software 6.5.3 Usability of non-implantable parts 6.5.4 Data security and protection from harm caused by unauthorized information tampering 6 5.5 General requirements for risk management 5.6 Misconnection of parts of the active implantable medical device 6 Measurements of implantable pulse generator and lead characteristics 6 6.1 Measurement of implantable pulse generator characteristics 6 6.1.1 General considerations 6 6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate 6 6.1.3 Measurement of sensitivity (epos and eng) 7 6.1.4 Measurement of sensitivity (epos and eng) 7 6.1.5 Measurement of sensitivity (epos and eng) 7 6.1.6 Measurement of sensitivity (epos and eng) 8 6.1.5 Measurement of sensing refractory period (tp) 8 6.1.6 Measurement of sensing refractory period (tp) 8 6.1.8 Measurement of Sensing refractory period (tp) 8 6.1.9 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators) 8 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 8 6.1.10 Measurement of the betapulse generators with atrial sensing and ventricular pacing) 9 Measurement of the packaging 15 9 Measurement of the lead pacing impedance (Zp) 10 6.2.1 Measurement of the lead pacing impedance (Zp) 11 Measurement of the packaging 18 12 General arrangement of the packaging 18 13 General markings for active implantable medical devices 18 14 Measurement of the packaging 18 15 General markings for active implantable medical devices 18 16 General markings for active implantable medical device 19 17 General markings for active implantable medical device 19 18 Markings on the sales packaging 19 19 Markings on the sales packaging 19 10 Construction of the non-reusable pack 20 11 Markings on t							
5 General requirements for non-implantable parts 6 5.1 General requirements for non-implantable parts 6 5.2 General requirements for non-implantable parts 6 5.3 Usability of non-implantable parts 6 5.4 Data security and protection from harm caused by unauthorized information tampering 6 5.5 General requirements for risk management 6 5.6 Misconnection of parts of the active implantable medical device 6 6 Measurements of implantable pulse generator and lead characteristics 6 6.1 Measurement of implantable pulse generator characteristics 6 6.1.1 General considerations 6 6.1.2 Measurement of implantable pulse generator characteristics 6 6.1.3 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.4 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.5 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.6 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 8 6.1.7 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.8 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.9 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.1 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.2 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.3 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.4 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.5 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.6 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 1 6.1.7 Measurement of pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators) 1 6.1.8 Measurement of the pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators) 1 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 1 6.1.9 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 1 6.2 Measurement of the lead pacing impedance (Z <sub>p</sub> ) 1 6.2 Measurement of the packaging 15 6.2 Measurement of the pack							
5.1 General requirements for non-implantable parts 5.2 General requirements for software 5.3 Usability of non-implantable parts 5.4 Data security and protection from harm caused by unauthorized information tampering 6 5.5 General requirements for risk management 5.6 Misconnection of parts of the active implantable medical device 6 Measurements of implantable pulse generator and lead characteristics 6 6.1 Measurement of implantable pulse generator characteristics 6 6.1.1 General considerations 6 6.1.2 Measurement of julse amplitude, pulse duration, pulse interval, and pulse rate 6 6.1.3 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.4 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.5 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.6 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.7 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.8 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.9 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.0 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.1 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.2 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.3 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.4 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 7 6.1.7 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 8 6.1.8 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 8 6.1.9 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 8 6.1.0 Measurement of the post-ventricular atrial refractory period (PVARP) 8 (applicable only to implantable pulse generators) 13 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) 14 6.1.10 Measurement of the atrial-ventricular (applicable only to dual-chamber implantable pulse generators with atrial sensing and ventricular pacing) 15 6.2 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 15 6.2 Measurement of the lead pacing impedance 16 6.2.1 Measurement of the lead pacing impedance 17 General	_	-					
5.2 General requirements for software.  5.3 Usability of non-implantable parts  5.4 Data security and protection from harm caused by unauthorized information tampering 6  5.5 General requirements for risk management  6. Misconnection of parts of the active implantable medical device  6 Measurements of implantable pulse generator and lead characteristics  6 6.1 Measurement of implantable pulse generator characteristics  6 6.1.1 General considerations  6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate  6 6.1.3 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate  6 6.1.4 Measurement of input impedance (Z <sub>in</sub> )  6 6.1.5 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> )  6 6.1.6 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> )  6 6.1.7 Measurement of sensity refractory period (t <sub>sr</sub> )  6 6.1.8 Measurement of sensing refractory period (t <sub>gr</sub> )  6 6.1.9 Measurement of pacing refractory period (t <sub>gr</sub> ) (applicable only to inhibited implantable pulse generators)  6 6.1.9 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators)  6 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing)  6 6 6 7 10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing)  6 8 10 Measurement of the lead pacing impedance (Z <sub>p</sub> )  6 10 Measurement of the lead pacing impedance  6 10 Measurement of the packaging  11 Markings on the sales packaging  12 Markings on the sales packaging  13 Markings on the sales packaging  14 Protection from harm to the patient or user caused by external physical features of	5	General requirements for non-implantable parts					
5.3 Usability of non-implantable parts 5.4 Data security and protection from harm caused by unauthorized information tampering 6 5.5 General requirements for risk management 5.6 Misconnection of parts of the active implantable medical device 6 6 Measurement of implantable pulse generator and lead characteristics 6 6.1 Measurement of implantable pulse generator characteristics 6.1.1 General considerations 6.1.2 Measurement of julse amplitude, pulse duration, pulse interval, and pulse rate 6.1.3 Measurement of sensitivity (epos and eneg) 7 6.1.4 Measurement of input impedance (Z <sub>[n]</sub> ) 8 6.1.5 Measurement of sensitivity (epos and eneg) 7 6.1.4 Measurement of sensitivity (epos and eneg) 8 6.1.5 Measurement of sensing refractory period (t <sub>st</sub> ) 8 6.1.6 Measurement of sensing refractory period (t <sub>st</sub> ) 8 6.1.7 Measurement of pacing refractory period (t <sub>st</sub> ) 8 6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators) 7 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 8 6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 9 6.2 Measurement of the atrial-ventricular (AV) interval after sensing and ventricular pacing) 15 6.2 Measurement of the atrial-ventricular (AV) interval after sensing and ventricular pacing) 16 6.2.1 Measurement of the atrial-ventricular (AV) interval after sensing and ventricular pacing) 17 6.1 Measurement of the atrial-ventricular (AV) interval after sensing and ventricular pacing) 18 6.2 Measurement of the packaging impedance (Z <sub>p</sub> ) 16 6.2.1 Measurement of the packaging impedance 17 6.2.1 Measurement of the packaging impedance 18 6.2.2 Methods of measuring lead pacing impedance 19 6.2.3 In vitro method for measuring lead pacing impedance 10 6.2.1 Measurement of the packaging impedance 11 6.2.2 Methods of measuring lead pacing impedan			Genera	requirements for non-implantable parts	b		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							
5.5 General requirements for risk management 6.6 Misconnection of parts of the active implantable medical device 6.1 Misconnection of parts of the active implantable medical device 6.1 Measurement of implantable pulse generator characteristics 6.1 Measurement of implantable pulse generator characteristics 6.1.1 General considerations 6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate 6.1.3 Measurement of sensitivity (epos and eneg) 7.6.1.4 Measurement of input impedance (Z <sub>in</sub> ) 8.6.1.5 Measurement of escape interval (t <sub>e</sub> ) 8.6.1.6 Measurement of sensing refractory period (t <sub>pr</sub> ) 10.6.1.7 Measurement of sensing refractory period (t <sub>pr</sub> ) 10.6.1.8 Measurement of pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators) 13.6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators) 13.6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 14.6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 15.6.2 Measurement of the lead pacing impedance (Z <sub>p</sub> ) 16.6.2.1 Measurement of the lead pacing impedance (Z <sub>p</sub> ) 16.6.2.1 Measurement of the lead pacing impedance (Z <sub>p</sub> ) 16.6.2.1 Methods of measuring lead pacing impedance 17.7 General arrangement of the packaging 18.8 General markings for active implantable medical devices 18.9 Markings on the sales packaging 18.0 Construction of the sales packaging 20.0 Markings on the sales packaging 20.0 Markings on the sterile pack 20.0 Construction of the non-reusable pack 21.0 Markings on the active implantable medical device 22.0 Markings on the active implantable medical device 22.0 Protection from unintentional biological effects being caused by the active implantable medical device 23.0 Protection from harm to the patient or user caused by external physical f							
		5.5	Genera	l requirements for risk management	6		
6.1 Measurement of implantable pulse generator characteristics 6 6.1.1 General considerations 6 6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate 6 6.1.3 Measurement of sensitivity (epos and eneg) 7 6.1.4 Measurement of input impedance (Zin) 8 6.1.5 Measurement of sensing refractory period (tsr) 8 6.1.6 Measurement of sensing refractory period (tsr) 10 6.1.7 Measurement of pacing refractory period (tpr) (applicable only to inhibited implantable pulse generators) 13 6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators) 13 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 14 6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 15 6.2 Measurement of the lead pacing impedance (Zp) 16 6.2.1 Measurement equipment accuracy 16 6.2.2 Methods of measuring lead pacing impedance 16 6.2.3 In vitro method for measurement of lead pacing impedance 17 7 General arrangement of the packaging 18 8 General markings for active implantable medical devices 18 9 Markings on the sales packaging 20 11 Markings on the sterile pack 20 12 Construction of the non-reusable pack 21 13 Markings on the active implantable medical device 22 14 Protection from unintentional biological effects being caused by the active implantable medical device 23		5.6	Miscon	nection of parts of the active implantable medical device	6		
6.1 Measurement of implantable pulse generator characteristics 6 6.1.1 General considerations 6 6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate 6 6.1.3 Measurement of sensitivity (epos and eneg) 7 6.1.4 Measurement of input impedance (Zin) 8 6.1.5 Measurement of sensing refractory period (tsr) 8 6.1.6 Measurement of sensing refractory period (tsr) 10 6.1.7 Measurement of pacing refractory period (tpr) (applicable only to inhibited implantable pulse generators) 13 6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators) 13 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 14 6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 15 6.2 Measurement of the lead pacing impedance (Zp) 16 6.2.1 Measurement equipment accuracy 16 6.2.2 Methods of measuring lead pacing impedance 16 6.2.3 In vitro method for measurement of lead pacing impedance 17 7 General arrangement of the packaging 18 8 General markings for active implantable medical devices 18 9 Markings on the sales packaging 20 11 Markings on the sterile pack 20 12 Construction of the non-reusable pack 21 13 Markings on the active implantable medical device 22 14 Protection from unintentional biological effects being caused by the active implantable medical device 23	6	Meas	uremen	ts of implantable pulse generator and lead characteristics	6		
6.1.2 Measurement of pulse amplitude, pulse duration, pulse interval, and pulse rate 6.1.3 Measurement of input impedance (Z <sub>in</sub> ) 6.1.4 Measurement of input impedance (Z <sub>in</sub> ) 6.1.5 Measurement of sensitivity (e <sub>pos</sub> and e <sub>neg</sub> ) 6.1.6 Measurement of sensing refractory period (t <sub>sr</sub> ) 6.1.7 Measurement of sensing refractory period (t <sub>sr</sub> ) 6.1.8 Measurement of Pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators) 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 6.1.10 Measurement of the tentral-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing) 6.2 Measurement of the lead pacing impedance (Z <sub>p</sub> ) 6.2.1 Measurement equipment accuracy 6.2.2 Methods of measuring lead pacing impedance 6.2.3 In vitro method for measurement of lead pacing impedance 7 General arrangement of the packaging 8 General markings for active implantable medical devices 18 9 Markings on the sales packaging 10 Construction of the sales packaging 20 11 Markings on the sterile pack 21 22 24 25 26 27 27 28 28 29 29 20 20 20 20 20 21 20 21 21 21 22 23 24 25 26 26 27 27 27 28 28 29 29 20 20 20 20 20 20 20 20 20 21 20 21 21 21 22 23 24 25 26 26 27 27 28 28 29 29 20 20 20 20 20 20 20 20 20 20 20 20 20			Measui	rement of <i>implantable pulse generator</i> characteristics	6		
Pulse rate   6   6.1.3   Measurement of sensitivity (epos and epos)   7   8   6.1.4   Measurement of input impedance (Zin)   8   8   6.1.5   Measurement of escape interval (tepos)   8   8   6.1.6   Measurement of sensing refractory period (tepos)   8   8   6.1.7   Measurement of pacing refractory period (tepos)   8   6.1.8   Measurement of AV interval (applicable only to dual-chamber implantable pulse generators)   13   6.1.8   Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators)   13   6.1.9   Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing)   14   6.1.10   Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing)   15   6.2   Measurement of the lead pacing impedance (Zp)   16   6.2.1   Measurement equipment accuracy   16   6.2.2   Methods of measuring lead pacing impedance   16   6.2.3   In vitro method for measurement of lead pacing impedance   17   7   General arrangement of the packaging   18   General markings for active implantable medical devices   18   Markings on the sales packaging   20   Markings on the sales packaging   21   Markings on the sterile pack   22   22   24   Protection from unintentional biological effects being caused by the active implantable medical device   22   Protection from harm to the patient or user caused by external physical features of			-		6		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			6.1.2		6		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			613				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				Measurement of input impedance ( $\mathbf{Z}_{i}$ )	/ 8		
6.1.6 Measurement of sensing refractory period (t <sub>sr</sub> ). 6.1.7 Measurement of pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators). 6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators). 6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing). 6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing). 6.2 Measurement of the lead pacing impedance (Z <sub>p</sub> ). 6.3 Measurement of the lead pacing impedance (Z <sub>p</sub> ). 6.4 Measurement equipment accuracy. 6.6 Methods of measuring lead pacing impedance. 6.2 Methods of measuring lead pacing impedance. 6.2 Methods of measurement of lead pacing impedance. 6.2 Methods of measurement of lead pacing impedance. 16 Methods of measurement of lead pacing impedance. 17 General arrangement of the packaging. 18 General markings for active implantable medical devices. 19 Markings on the sales packaging. 10 Construction of the sales packaging. 20 Markings on the sterile pack. 21 Construction of the non-reusable pack. 22 Markings on the active implantable medical device. 23 Protection from unintentional biological effects being caused by the active implantable medical device. 23 Protection from harm to the patient or user caused by external physical features of				Measurement of <b>escape interval</b> $(t_0)$	8		
6.1.7 Measurement of pacing refractory period (t <sub>pr</sub> ) (applicable only to inhibited implantable pulse generators)			6.1.6	Measurement of sensing <i>refractory period</i> ( $t_{\rm sr}$ )	10		
6.1.8 Measurement of AV interval (applicable only to dual-chamber implantable pulse generators).  6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing).  6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to implantable pulse generators with atrial sensing and ventricular pacing).  6.2 Measurement of the lead pacing impedance (Z <sub>p</sub> ).  6.2.1 Measurement equipment accuracy.  6.2.2 Methods of measuring lead pacing impedance  6.2.3 In vitro method for measurement of lead pacing impedance  6.2.3 In vitro method for measurement of lead pacing impedance  7 General arrangement of the packaging  8 General markings for active implantable medical devices  18 Markings on the sales packaging  19 Markings on the sales packaging  20 Construction of the sales packaging  21 Markings on the sterile pack  22 Markings on the active implantable medical device  23 Protection from unintentional biological effects being caused by the active implantable medical device  23 Protection from harm to the patient or user caused by external physical features of			6.1.7	Measurement of pacing <i>refractory period</i> $(t_{pr})$ (applicable only to			
implantable pulse generators)				inhibited <i>implantable pulse generators</i> )	13		
6.1.9 Measurement of the post-ventricular atrial refractory period (PVARP) (applicable only to implantable pulse generators with atrial sensing and ventricular pacing)			6.1.8	Measurement of AV interval (applicable only to dual-chamber	10		
(applicable only to <i>implantable pulse generators</i> with atrial sensing and ventricular pacing)			610		13		
ventricular pacing)			0.1.9	(applicable only to <b>implantable pulse generators</b> with atrial sensing and			
6.1.10 Measurement of the atrial-ventricular (AV) interval after sensing (applicable only to <i>implantable pulse generators</i> with atrial sensing and ventricular pacing)					14		
ventricular pacing)			6.1.10				
6.2 Measurement of the lead pacing impedance (Z <sub>p</sub> )							
6.2.1 Measurement equipment accuracy 16 6.2.2 Methods of measuring lead pacing impedance 16 6.2.3 In vitro method for measurement of lead pacing impedance 17  General arrangement of the packaging 18  General markings for active implantable medical devices 18  Markings on the sales packaging 18  Construction of the sales packaging 20  Markings on the sterile pack 20  Construction of the non-reusable pack 22  Markings on the active implantable medical device 22  Markings on the active implantable medical device 22  Protection from unintentional biological effects being caused by the active implantable medical device 23  Protection from harm to the patient or user caused by external physical features of				ventricular pacing)	15		
6.2.2 Methods of measuring lead pacing impedance 16 6.2.3 In vitro method for measurement of lead pacing impedance 17  General arrangement of the packaging 18  General markings for active implantable medical devices 18  Markings on the sales packaging 18  Construction of the sales packaging 20  Markings on the sterile pack 20  Construction of the non-reusable pack 22  Markings on the active implantable medical device 22  Markings on the active implantable medical device 22  Protection from unintentional biological effects being caused by the active implantable medical device 23  Protection from harm to the patient or user caused by external physical features of		6.2	Measui	rement of the <i>lead pacing impedance</i> $(\mathbf{Z}_{\mathrm{p}})$	16		
6.2.3 In vitro method for measurement of lead pacing impedance				Methods of measuring <i>lead nacina impedance</i>	10 16		
7 General arrangement of the packaging				In vitro method for measurement of <i>lead pacing impedance</i>	17		
8 General markings for active implantable medical devices	7	Gene	ral arrai				
9 Markings on the sales packaging		Gene	ral mark	rings for active implantable medical devices	18		
10 Construction of the sales packaging 20 11 Markings on the sterile pack 20 12 Construction of the non-reusable pack 22 13 Markings on the active implantable medical device 22 14 Protection from unintentional biological effects being caused by the active implantable medical device 23 15 Protection from harm to the patient or user caused by external physical features of							
Markings on the sterile pack							
Construction of the non-reusable pack 22  Markings on the active implantable medical device 22  Protection from unintentional biological effects being caused by the active implantable medical device 23  Protection from harm to the patient or user caused by external physical features of							
Markings on the active implantable medical device							
Protection from unintentional biological effects being caused by the active implantable medical device23  Protection from harm to the patient or user caused by external physical features of							
implantable medical device 23  Protection from harm to the patient or user caused by external physical features of					22		
	14				23		
	15						

medical device	23
Protection from unintended effects caused by the device Protection of the device from damage caused by external defibrillators Protection of the device from changes caused by high power electrical fields applied directly to the patient Protection of the active implantable medical device from changes caused by miscellaneous medical treatments Protection of the active implantable medical device from mechanical forces Protection of the active implantable medical device from damage caused by electrostatic discharge Protection of the active implantable medical device from damage caused by atmospheric pressure changes Protection of the active implantable medical device from damage caused by temperature changes Protection of the active implantable medical device from damage caused by temperature changes Protection of the active implantable medical device from electromagnetic nonionizing radiation Rannex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document Annex B (informative) Rationale Annex C (informative) Code for describing modes of implantable pulse generators Annex D (normative) Pulse forms	25
Protection of the device from damage caused by external defibrillators  21 Protection of the device from changes caused by high power electrical fields applied directly to the patient  22 Protection of the active implantable medical device from changes caused by miscellaneous medical treatments  23 Protection of the active implantable medical device from mechanical forces  24 Protection of the active implantable medical device from damage caused by electrostatic discharge  25 Protection of the active implantable medical device from damage caused by atmospheric pressure changes  26 Protection of the active implantable medical device from damage caused by temperature changes  27 Protection of the active implantable medical device from electromagnetic nonionizing radiation  28 Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	25
Protection of the device from changes caused by high power electrical fields applied directly to the patient.  Protection of the active implantable medical device from changes caused by miscellaneous medical treatments  Protection of the active implantable medical device from mechanical forces.  Protection of the active implantable medical device from damage caused by electrostatic discharge.  Protection of the active implantable medical device from damage caused by atmospheric pressure changes.  Protection of the active implantable medical device from damage caused by temperature changes.  Protection of the active implantable medical device from electromagnetic nonionizing radiation.  Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document.  Annex B (informative) Rationale.  Annex C (informative) Code for describing modes of implantable pulse generators.  Annex D (normative) Pulse forms.	26
Protection of the device from changes caused by high power electrical fields applied directly to the patient.  Protection of the active implantable medical device from changes caused by miscellaneous medical treatments  Protection of the active implantable medical device from mechanical forces.  Protection of the active implantable medical device from damage caused by electrostatic discharge.  Protection of the active implantable medical device from damage caused by atmospheric pressure changes.  Protection of the active implantable medical device from damage caused by temperature changes.  Protection of the active implantable medical device from electromagnetic nonionizing radiation.  Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document.  Annex B (informative) Rationale.  Annex C (informative) Code for describing modes of implantable pulse generators.  Annex D (normative) Pulse forms.	27
miscellaneous medical treatments  23 Protection of the active implantable medical device from mechanical forces  24 Protection of the active implantable medical device from damage caused by electrostatic discharge.  25 Protection of the active implantable medical device from damage caused by atmospheric pressure changes  26 Protection of the active implantable medical device from damage caused by temperature changes  27 Protection of the active implantable medical device from electromagnetic nonionizing radiation  28 Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	
24 Protection of the active implantable medical device from damage caused by electrostatic discharge	27
electrostatic discharge  25 Protection of the active implantable medical device from damage caused by atmospheric pressure changes  26 Protection of the active implantable medical device from damage caused by temperature changes  27 Protection of the active implantable medical device from electromagnetic non-ionizing radiation  28 Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	27
atmospheric pressure changes  26 Protection of the active implantable medical device from damage caused by temperature changes  27 Protection of the active implantable medical device from electromagnetic non-ionizing radiation  28 Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	31
27 Protection of the active implantable medical device from electromagnetic non- ionizing radiation  28 Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	31
ionizing radiation  28 Accompanying documentation  Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	32
Annex A (informative) Relationship between the fundamental principles in ISO/TR 14283 and the clauses of this document  Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	
Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	32
Annex B (informative) Rationale  Annex C (informative) Code for describing modes of implantable pulse generators  Annex D (normative) Pulse forms	
Annex D (normative) <i>Pulse</i> forms	57
Bibliography	
	70
	5

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see <a href="www.iso.org/directives">www.iso.org/directives</a>).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see <a href="https://www.iso.org/patents">www.iso.org/patents</a>).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see <a href="https://www.iso.org/iso/foreword.html">www.iso.org/iso/foreword.html</a>.

ISO 14708-2 was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 6, *Active implants*.

This third edition cancels and replaces the second edition (ISO 14708-2:2012), which has been technically revised.

The main changes compared to the previous edition are as follows:

- addition of requirements for congestive heart failure devices;
- introduction of nomenclature for devices having more than two channels of pacing / sensing as shown in ISO 14117:2019, Annex N;
- revision of the method for measurement of *pulse amplitude* and *pulse duration* in 6.1.2;
- removal of measurement requirements for input impedance in 6.1.4;
- inclusion of new temporary exposure criteria in <u>17.1</u> for outer surface temperatures exceeding 39 °C. Other changes include updates to selected definitions and incorporation of new measurement equipment accuracy requirements.

A list of all parts in the ISO 14708 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at <a href="https://www.iso.org/members.html">www.iso.org/members.html</a>.

# Introduction

This document specifies particular requirements for those active implantable medical devices intended to treat bradyarrhythmias (*pacemakers*), to provide basic assurance of safety to both patients and users.

In recent years, other active implantable cardiovascular devices have emerged, most notably devices that perform the function of improving cardiac output by optimizing ventricular synchrony, in addition to performing *pacemaker* functions.

Although these devices can deliver an additional therapy with respect to *pacemakers*, most of their requirements are similar so that, in most cases, the concepts that apply to *pacemakers* also apply to *CRT-P* device, and the appropriate way to test a *CRT-P* device is similar to the way *pacemakers* are tested.

An implantable cardiac *pacemaker* is essentially a powered electronic device within a sealed, encapsulating enclosure (an *implantable pulse generator*). The device can stimulate heart *beats* by generating electrical impulses which are transmitted to the heart along implanted, insulated conductors with *electrodes* (leads). The *pacemaker* can be adjusted non-invasively by an electronic device, known as a programmer.

This document is relevant to all parts of implantable *pacemakers*, including all *accessories*. Typical examples are *implantable pulse generators*, leads, *adaptors*, programmers and the related software.

The requirements of this document supplement or modify those of ISO 14708-1. The requirements of this document take priority over those of ISO 14708-1.

Although both this document and the Directive 90/385/EEC deal with the same products, the structure and purpose of the two documents are different. Annex A correlates the requirements of the Directive with the subclauses of ISO 14708-1 and this document. Annex B is a rationale providing further explanation of the subclauses of this document.

Annex C describes a coding system that may be used to designate bradyarrhythmia pacing modes. Annex D defines reference points for measurements of *pulse amplitude* and *pulse duration*, and the form of test signal used to determine *sensitivity*.

All annexes except **Annex D** are informative.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

# Implants for surgery — Active implantable medical devices —

# Part 2:

# Cardiac pacemakers

# 1 Scope

This document specifies requirements that are applicable to those active implantable medical devices intended to treat bradyarrhythmias and devices that provide therapies for cardiac resynchronization.

The tests that are specified in this document are type tests, and are to be carried out on samples of a device to show compliance.

This document was designed for bradyarrhythmia *pulse* generators used with *endocardial leads* or *epicardial leads*. At the time of this edition, the authors recognized the emergence of leadless technologies for which adaptations of this part will be required. Such adaptations are left to the discretion of manufacturers incorporating these technologies.

This document is also applicable to some non-implantable parts and *accessories* of the devices (see Note 1).

The electrical characteristics of the *implantable pulse generator* or lead are determined either by the appropriate method detailed in this particular standard or by any other method demonstrated to have an accuracy equal to, or better than, the method specified. In case of dispute, the method detailed in this particular standard applies.

Any features of an active implantable medical device intended to treat tachyarrhythmias are covered by ISO 14708-6.

NOTE 1 The device that is commonly referred to as an active implantable medical device can in fact be a single device, a combination of devices, or a combination of a device or devices and one or more *accessories*. Not all of these parts are required to be either partially or totally implantable, but there is a need to specify some requirements of non-implantable parts and *accessories* if they could affect the safety or performance of the implantable device.

NOTE 2 In this document, terms printed in italics are used as defined in <u>Clause 3</u>. Where a defined term is used as a qualifier in another term, it is not printed in italics unless the concept thus qualified is also defined.

#### 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 5841-3:2013, Implants for surgery — Cardiac pacemakers — Part 3: Low-profile connectors (IS-1) for implantable pacemakers

ISO 11318:2002, Cardiac defibrillators — Connector assembly DF-1 for implantable defibrillators — Dimensions and test requirements

ISO 14117:2019, Active implantable medical devices — Electromagnetic compatibility — EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators and cardiac resynchronization devices, Second Edition

ISO 14708-1:2014, Implants for surgery — Active implantable medical devices — Part 1: General requirements for safety, marking and for information to be provided by the manufacturer

ISO 27186:2010, Active implantable medical devices — Four-pole connector system for implantable cardiac rhythm management devices — Dimensional and test requirements

#### 3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 14708-1 and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <a href="https://www.iso.org/obp">https://www.iso.org/obp</a>
- IEC Electropedia: available at <a href="http://www.electropedia.org/">http://www.electropedia.org/</a>

#### 3.1

#### accessorv

article which, while not being a device, is intended specifically by the manufacturer to be used together with a device in accordance with the use of the device intended by the device manufacturer

#### 3.2

#### adaptor

special connector used between an otherwise incompatible implantable pulse generator and a lead

#### 3.3

#### pacemaker

active implantable medical device intended to treat bradyarrhythmias, comprising an *implantable pulse generator* and lead(s)

#### 3.4

## implantable pulse generator

part of the pacemaker, including the power supply and electronic circuit that produces an electrical output

#### 3.5

#### sensor

part of a *pacemaker* that is designed to detect signals for the purpose of *rate modulation* or other control purposes

#### 3.6

#### dual-chamber

condition of relating both to the atrium and ventricle

#### 3.7

# implantable cardiac resynchronization therapy pacing device CRT-P

active implantable medical device intended to provide improved ventricular activation to optimize cardiac output, comprising an *implantable pulse generator* and leads

#### 3.8

#### sensitivity

minimum signal required to control consistently the function of the implantable pulse generator

## 3.9

#### electrode

electrically conducting part (usually the termination of a lead), which is designed to form an interface with body tissue or body fluid

#### 3.10

#### bipolar lead

lead with two *electrodes*, electrically isolated from each other